top of page
Search

SL Science Holding Limited Completes Business Combination and Lists on the Nasdaq Global Market (Formerly known as SL BIO Ltd.)

  • 22 hours ago
  • 5 min read

Updated: 14 minutes ago


Chairman William Wang of SL Science Holding Limited (Nasdaq: SLBT)
Chairman William Wang of SL Science Holding Limited (Nasdaq: SLBT)

Date: June 15, 2026


Formerly known as SL BIO Ltd., SL Science Holding Limited (Nasdaq: SLBT) today commenced trading on the Nasdaq Global Market, marking the official completion of its business combination with Horizon Space Acquisition II Corp. (Nasdaq: HSPT). This milestone represents a defining moment in the company’s mission to develop scalable, accessible cellular therapies for patients with solid tumor cancers.


The business combination was approved by Horizon Space shareholders at an extraordinary general meeting on February 12, 2026. The transaction carries an implied equity valuation of approximately $5.568 billion and was accompanied by the concurrent closing of a $7.8 million PIPE financing, providing SL Science with strategic capital to accelerate its clinical and commercial growth initiatives.


Strategic Capital to Advance Proprietary Cell Therapy Platforms

The proceeds from this transaction will support the advancement of SL Science’s proprietary Gamma Delta T (“GDT”) cell-based cellular therapy platforms through preclinical development and planned clinical trials. The company’s initial pipeline targets solid tumor indications with significant unmet medical need, including pancreatic cancer and glioblastoma (brain cancer).


Unlike traditional autologous cell therapies that depend on patient-specific cell manufacturing, SL Science’s GDT cell approach is allogeneic — derived from healthy donors and designed to be scalable and ready for use. The company has filed a U.S. FDA Drug Master File for its unmodified Vδ2+ GDT cells, establishing a regulatory foundation for future clinical submissions.


Applying Semiconductor Industry Logic to Cell Therapy

At the listing, Chairman and CEO William Wang articulated the company’s defining vision: “In the global oncology market, cell therapy is widely recognized as one of the most transformative approaches. However, it has yet to scale into a true global industry due to three core limitations: lack of standardization, limited manufacturing capacity, and extremely high costs.”


“SL Science plans to bring standardization and scalable manufacturing to cell therapy — shifting it from a highly customized medical procedure into a platform-based, modular, scalable, and reproducible business model. We believe our technology is not just a new approach, but a global platform that may extend beyond oncology, into the future of immune-based medicine worldwide,” Wang added.


Expanded Leadership Team and Board of Directors

SL Science has established a seasoned executive team and board of directors. William Wang serves as Chief Executive Officer and Chairman, alongside Ray Leung as Chief Financial Officer, Johnson Lau as Vice President of Finance, and Ethan Shen, Ph.D., as Chief Technology Officer and Director.


The Board of Directors includes independent directors Joseph Levinson, Qian (Hebe) Xu, John C. General, Kwo-Liang Chen, and Mingche Liu, M.D., Ph.D., bringing collective expertise in accounting, cross-border corporate governance, investment banking, and medical sciences.


Access to Global Capital Markets

Trading on Nasdaq grants SL Science direct access to U.S. institutional capital markets. This enhanced financial flexibility will support the company in attracting top-tier global scientific talent, facilitating future strategic acquisitions, and securing international licensing partnerships — accelerating SL Science’s path toward becoming a platform-based leader in immune oncology.



Advisors

VCL Law LLP and Ogier acted as legal advisors to SL Science.

Robinson & Cole LLP and Maples Group acted as legal advisor to Horizon Space.


About SL Science Holding Limited

SL Science Holding Limited is a biomedical company specializing in developing innovative cellular and gene therapies. Established with a commitment to advancing regenerative medicine and cancer treatment, SL Science hopes to utilize immune cell technologies to target cancer, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Gamma Delta T cells targeting solid tumor indications including pancreatic and brain cancers, SL Science aims to create cellular therapies that we believe have the potential to revolutionize the cell therapy and immuno-oncology sector within the broader biopharmaceutical industry. For more information, please visit the company's website at: www.slbtgroup.com


About Horizon Space Acquisition II Corp.

Horizon Space Acquisition II Corp. is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities.


Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of the federal securities laws with respect to the completed business combination and the business of SL Science Holding Limited. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: the ability of the combined company to successfully implement its business plans and clinical trials; the ability to obtain and maintain necessary regulatory approvals for its product candidates; the potential for its regenerative medicine products to reach commercialization; and the ability to recognize the anticipated benefits of the business combination. The combined company assumes no obligation to update these forward-looking statements, except as required by applicable law.



Contact Details

SL Science Holding Limited

Tel: +886-2-26516826


WFS Investor Relations Inc.

Tel: +1 628 283 9214



Media Coverage

Comments

Commenting on this post isn't available anymore. Contact the site owner for more info.
bottom of page